Like my comment thanks_老虎社区_美港股上老虎

Abu888
2021-09-16

Like my comment thanks

3 COVID Stocks That Might Double Soon<blockquote>3只新冠股票可能很快翻倍</blockquote>

Here are three healthcare stocks as nominees for a quick double in 2021.

3 COVID Stocks That Might Double Soon<blockquote>3只新冠股票可能很快翻倍</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":885606416,"tweetId":"885606416","gmtCreate":1631781443235,"gmtModify":1631883968966,"author":{"id":3581658741892979,"idStr":"3581658741892979","authorId":3581658741892979,"authorIdStr":"3581658741892979","name":"Abu888","avatar":"https://static.tigerbbs.com/39dfd9ec19b4b4e5c99cbc270b33e932","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Like my comment thanks</body></html>","htmlText":"<html><head></head><body>Like my comment thanks</body></html>","text":"Like my comment thanks","highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/885606416","repostId":1195990706,"repostType":4,"repost":{"id":"1195990706","kind":"news","pubTimestamp":1631781148,"share":"https://www.laohunote.com/m/news/1195990706?lang=zh_CN&edition=full","pubTime":"2021-09-16 16:32","market":"us","language":"en","title":"3 COVID Stocks That Might Double Soon<blockquote>3只新冠股票可能很快翻倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1195990706","media":"Motley Fool","summary":"Here are three healthcare stocks as nominees for a quick double in 2021.","content":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.<blockquote>短期内任何事情都可能发生，所以说一只股票一定会快速翻倍是愚蠢的。尽管如此，这些 Fool.com 撰稿人仍然看好这三只医疗保健股，短期乐观是有理由的。</blockquote> Read more to find out why we think&nbsp;Novavax(NASDAQ:NVAX),&nbsp;Sorrento Therapeutics(NASDAQ:SRNE), and&nbsp;InMode(NASDAQ:INMD)will close out 2021 with a bang.<blockquote>阅读更多内容，了解我们为什么认为诺瓦瓦克斯（纳斯达克股票代码：NVAX），索伦托治疗公司（纳斯达克股票代码：SRNE），以及模式（纳斯达克股票代码：INMD）将以一声巨响结束 2021 年。</blockquote> <img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Multiple catalysts will make Novavax shares jump in 2021<blockquote>1. 多重催化剂将使 Novavax 股价在 2021 年跃升</blockquote> Taylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.<blockquote>泰勒·卡迈克尔（诺瓦瓦克斯）：Novavax 股价今年已经翻了一番，从 1 月份的 112 美元涨至本周的 233 美元。但是油箱里还有很多汽油，我预计到今年年底还会翻一番。</blockquote> Right now,Moderna&nbsp;enjoys a $169 billion market cap, and&nbsp;BioNTech&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.<blockquote>现在，现代享有1690亿美元的市值，并且生物技术体育估值790亿美元。与此同时，Novavax 的市值为 170 亿美元，价格非常便宜。当然，不同之处在于，mRNA biotechs 的两种 COVID-19 疫苗现在都已上市，而 Novavax 仍在等待其第一个紧急使用授权。但当政府机构开始允许 Novavax 分发其 COVID-19 疫苗时，该股将真正开始飙升。</blockquote> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.<blockquote>世界上大多数人口仍未接种疫苗。Novavax 将在 2022 年准备分发 20 亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.<blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。一剂要13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将打折。Novavax 明年的收入完全有可能高于目前的市值。</blockquote> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.<blockquote>我预计，随着 Novavax 疫苗在第四季度开始在世界各地获得授权，其股价将飙升。Novavax的候选疫苗将作为加强疫苗和世界上大多数未接种疫苗的人的初始疫苗而受欢迎。Novavax 在将 COVID-19 疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们一次性接种了这两种疾病的疫苗。</blockquote> 2. Sorrento Therapeutics: Don't sleep on this name<blockquote>2. Sorrento Therapeutics：不要睡在这个名字上</blockquote> George Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.<blockquote>乔治·布德威尔（索伦托治疗公司）：由于其令人印象深刻的实验性 COVID-19 诊断和生物疗法阵容，临床阶段生物技术 Sorrento Therapeutics 去年声名鹊起。事实上，这家生物技术公司的股价从 2020 年 1 月到 2021 年 3 月上涨了 144%，这主要是因为其广泛的 COVID-19 候选疫苗。然而，索伦托的股价在过去 180 天里已经下跌了近四分之一的价值。鉴于该公司甚至无法将其各种 COVID-19 候选疫苗中的一种推向市场，投资者显然已经转向了更绿色的领域。</blockquote> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.<blockquote>核心问题是，在过去的几个月里，多家生物制药公司在美国和欧盟等主要市场成功开发并随后销售了新冠肺炎疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎很可能演变成一种季节性呼吸道疾病。因此，投资者不一定会放弃索伦托等后来者。最终，该公司可以从新冠肺炎诊断和/或治疗中实现健康的收入流。</blockquote> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.<blockquote>索伦托完全有可能在下一个日历年内在美国获得其 COVID-19 候选疫苗的多个监管部门批准，这对其股票来说将是一个重大利好。也就是说，这只中型生物科技股肯定会保持波动，直到该公司在 COVID-19 领域获得美国食品药品监督管理局的批准。相应地投资。</blockquote> 3. InMode stock will spike as the world reopens<blockquote>3. 随着世界重新开放，InMode 股价将飙升</blockquote> Patrick Bafuma&nbsp;(InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.<blockquote>帕特里克·巴富马 （模式内）：随着世界重新开放，人们聚集在一起更加舒适，美学市场肯定会升温。这就是为什么我选择翻倍的 COVID-19 疫苗库存是 InMode，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，拥有强大的品牌知名度。</blockquote> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.<blockquote>该公司使用剃须刀和刀片模型，销售医疗设备系统和相关消耗品，为身体塑形提供能量来源。InMode被包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生在内的多名医学专家使用，声称其程序比激光治疗更持久，比吸脂等典型的塑身程序侵入性更小。</blockquote> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.<blockquote>这家价值 52 亿美元的美容公司正在全力以赴。在最近一个季度，InMode报告的收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外地区的总销售额为 3090 万美元，是去年同期的三倍多。这一强劲的国际增长占其总收入的 35%，而 2020 年第二季度占其总收入的 22%。该公司目前在68个国家开展业务，拥有巨大的持续增长空间。</blockquote> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"<blockquote>随着世界慢慢恢复正常，消费者正在寻求因新冠肺炎而推迟的治疗。“我们的需求很强劲，”首席医疗官 Spero Theodorou 在上次电话会议上指出。“一直到九月份，情况都很稳定。等候名单……（大约）一个月后就结束了。”</blockquote> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.<blockquote>西奥多鲁接着说：“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了身体轮廓市场，尽管有新冠肺炎疫情，2020年全球市场已经达到62亿美元。该市场预计到 2026 年将以 7.2% 的复合年增长率增长，因此 InMode 还有很大的发展空间。</blockquote> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.<blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美学设备制造商将继续增长。尽管InMode自2021年初以来已经上涨了180%以上，但该公司拥有巨大的跑道，其剃须刀和刀片商业模式仍然是一种有效的定位策略。InMode 已经实现盈利，第二季度调整后稀释每股收益为 1.02 美元，而 2020 年同季度稀释后每股收益为 0.24 美元。InMode 看起来有望再次将其股价翻倍。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Might Double Soon<blockquote>3只新冠股票可能很快翻倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Might Double Soon<blockquote>3只新冠股票可能很快翻倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-16 16:32\n\n</h4>\n</header>\n<article>\nAnything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.<blockquote>短期内任何事情都可能发生，所以说一只股票一定会快速翻倍是愚蠢的。尽管如此，这些 Fool.com 撰稿人仍然看好这三只医疗保健股，短期乐观是有理由的。</blockquote> Read more to find out why we think&nbsp;Novavax(NASDAQ:NVAX),&nbsp;Sorrento Therapeutics(NASDAQ:SRNE), and&nbsp;InMode(NASDAQ:INMD)will close out 2021 with a bang.<blockquote>阅读更多内容，了解我们为什么认为诺瓦瓦克斯（纳斯达克股票代码：NVAX），索伦托治疗公司（纳斯达克股票代码：SRNE），以及模式（纳斯达克股票代码：INMD）将以一声巨响结束 2021 年。</blockquote> <img src=\"https://static.tigerbbs.com/cf7858be2535b72fb5033e8b4d227614\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote> 1. Multiple catalysts will make Novavax shares jump in 2021<blockquote>1. 多重催化剂将使 Novavax 股价在 2021 年跃升</blockquote> Taylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.<blockquote>泰勒·卡迈克尔（诺瓦瓦克斯）：Novavax 股价今年已经翻了一番，从 1 月份的 112 美元涨至本周的 233 美元。但是油箱里还有很多汽油，我预计到今年年底还会翻一番。</blockquote> Right now,Moderna&nbsp;enjoys a $169 billion market cap, and&nbsp;BioNTech&nbsp;sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.<blockquote>现在，现代享有1690亿美元的市值，并且生物技术体育估值790亿美元。与此同时，Novavax 的市值为 170 亿美元，价格非常便宜。当然，不同之处在于，mRNA biotechs 的两种 COVID-19 疫苗现在都已上市，而 Novavax 仍在等待其第一个紧急使用授权。但当政府机构开始允许 Novavax 分发其 COVID-19 疫苗时，该股将真正开始飙升。</blockquote> The majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.<blockquote>世界上大多数人口仍未接种疫苗。Novavax 将在 2022 年准备分发 20 亿剂疫苗。该生物技术公司在世界各地签订了多项供应协议：向美国供应1亿剂，向日本供应1.5亿剂，向欧洲供应2亿剂，向发展中国家供应超过10亿剂。</blockquote> The U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its&nbsp;market cap&nbsp;today.<blockquote>美国预付了13亿美元，以获得该公司的1亿剂实验性疫苗。一剂要13美元。虽然各种购买协议的美元金额没有披露，但日本和欧洲可能会支付更高的美元金额，而发展中国家的协议将打折。Novavax 明年的收入完全有可能高于目前的市值。</blockquote> I'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.<blockquote>我预计，随着 Novavax 疫苗在第四季度开始在世界各地获得授权，其股价将飙升。Novavax的候选疫苗将作为加强疫苗和世界上大多数未接种疫苗的人的初始疫苗而受欢迎。Novavax 在将 COVID-19 疫苗与流感疫苗结合的竞赛中处于领先地位。该公司刚刚在澳大利亚启动了一项联合试验，涉及640人，他们一次性接种了这两种疾病的疫苗。</blockquote> 2. Sorrento Therapeutics: Don't sleep on this name<blockquote>2. Sorrento Therapeutics：不要睡在这个名字上</blockquote> George Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various&nbsp;COVID-19 vaccine candidates&nbsp;to market in the United States.<blockquote>乔治·布德威尔（索伦托治疗公司）：由于其令人印象深刻的实验性 COVID-19 诊断和生物疗法阵容，临床阶段生物技术 Sorrento Therapeutics 去年声名鹊起。事实上，这家生物技术公司的股价从 2020 年 1 月到 2021 年 3 月上涨了 144%，这主要是因为其广泛的 COVID-19 候选疫苗。然而，索伦托的股价在过去 180 天里已经下跌了近四分之一的价值。鉴于该公司甚至无法将其各种 COVID-19 候选疫苗中的一种推向市场，投资者显然已经转向了更绿色的领域。</blockquote> The core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.<blockquote>核心问题是，在过去的几个月里，多家生物制药公司在美国和欧盟等主要市场成功开发并随后销售了新冠肺炎疫苗、测试和治疗性抗体。与此同时，索伦托仍在寻求其首次重大监管胜利。然而，对于潜在投资者来说，重要的是要明白，疫情还远未结束。新冠肺炎很可能演变成一种季节性呼吸道疾病。因此，投资者不一定会放弃索伦托等后来者。最终，该公司可以从新冠肺炎诊断和/或治疗中实现健康的收入流。</blockquote> It is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.<blockquote>索伦托完全有可能在下一个日历年内在美国获得其 COVID-19 候选疫苗的多个监管部门批准，这对其股票来说将是一个重大利好。也就是说，这只中型生物科技股肯定会保持波动，直到该公司在 COVID-19 领域获得美国食品药品监督管理局的批准。相应地投资。</blockquote> 3. InMode stock will spike as the world reopens<blockquote>3. 随着世界重新开放，InMode 股价将飙升</blockquote> Patrick Bafuma&nbsp;(InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.<blockquote>帕特里克·巴富马 （模式内）：随着世界重新开放，人们聚集在一起更加舒适，美学市场肯定会升温。这就是为什么我选择翻倍的 COVID-19 疫苗库存是 InMode，该公司自称是全球领先的创新、微创美容和健康解决方案提供商，拥有强大的品牌知名度。</blockquote> Using a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.<blockquote>该公司使用剃须刀和刀片模型，销售医疗设备系统和相关消耗品，为身体塑形提供能量来源。InMode被包括整形外科医生、皮肤科医生、妇科医生、耳鼻喉科医生和眼科医生在内的多名医学专家使用，声称其程序比激光治疗更持久，比吸脂等典型的塑身程序侵入性更小。</blockquote> And this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.<blockquote>这家价值 52 亿美元的美容公司正在全力以赴。在最近一个季度，InMode报告的收入达到创纪录的8730万美元，与2020年第二季度相比增长了184%。第二季度美国以外地区的总销售额为 3090 万美元，是去年同期的三倍多。这一强劲的国际增长占其总收入的 35%，而 2020 年第二季度占其总收入的 22%。该公司目前在68个国家开展业务，拥有巨大的持续增长空间。</blockquote> As the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"<blockquote>随着世界慢慢恢复正常，消费者正在寻求因新冠肺炎而推迟的治疗。“我们的需求很强劲，”首席医疗官 Spero Theodorou 在上次电话会议上指出。“一直到九月份，情况都很稳定。等候名单……（大约）一个月后就结束了。”</blockquote> Theodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.<blockquote>西奥多鲁接着说：“超过三分之一的新患者以前从未做过（任何美容手术）。”这表明InMode已经扩大了身体轮廓市场，尽管有新冠肺炎疫情，2020年全球市场已经达到62亿美元。该市场预计到 2026 年将以 7.2% 的复合年增长率增长，因此 InMode 还有很大的发展空间。</blockquote> With many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.<blockquote>自2020年3月以来，我们中的许多人要么呆在家里，要么戴着面具，我预计随着新冠肺炎的衰落，这家美学设备制造商将继续增长。尽管InMode自2021年初以来已经上涨了180%以上，但该公司拥有巨大的跑道，其剃须刀和刀片商业模式仍然是一种有效的定位策略。InMode 已经实现盈利，第二季度调整后稀释每股收益为 1.02 美元，而 2020 年同季度稀释后每股收益为 0.24 美元。InMode 看起来有望再次将其股价翻倍。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","INMD":"InMode Ltd.","SRNE":"索伦托医疗"},"source_url":"https://www.fool.com/investing/2021/09/15/3-covid-stocks-that-might-double-soon/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195990706","content_text":"Anything can happen in the short term, so it's folly to say that a stock is a sure thing for a quick double. Nonetheless, these Fool.com contributors are bullish on these three healthcare stocks, and there are reasons for short-term optimism.\nRead more to find out why we think Novavax(NASDAQ:NVAX), Sorrento Therapeutics(NASDAQ:SRNE), and InMode(NASDAQ:INMD)will close out 2021 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\n1. Multiple catalysts will make Novavax shares jump in 2021\nTaylor Carmichael(Novavax):Novavax stock has already doubled this year, running from $112 back in January to $233 this week. But there's plenty of gas left in the tank, and I expect another double by the end of the year.\nRight now,Moderna enjoys a $169 billion market cap, and BioNTech sports a $79 billion valuation. Meanwhile, Novavax is positively cheap with its $17 billion market cap. The difference, of course, is that the mRNA biotechs have both of their COVID-19 vaccines on the market now, while Novavax is still waiting for its first Emergency Use Authorization. But when the government agencies start allowing Novavax to distribute its COVID-19 vaccine, the stock will really start to soar.\nThe majority of the world's population still has not been vaccinated. Novavax will have 2 billion doses of vaccine ready to distribute in 2022. And the biotech has multiple agreements for supplying locations around the world: 100 million doses for the U.S., 150 million doses for Japan, 200 million doses for Europe, and over 1 billion doses for the developing world.\nThe U.S. paid $1.3 billion in advance to secure its 100 million doses of the company's experimental vaccine. That works out to $13 a dose. While the dollar amounts of the various purchase agreements are undisclosed, Japan and Europe will likely pay a higher dollar amount, while the developing world agreements will be discounted. It's entirely possible that Novavax's revenue next year will be higher than its market cap today.\nI'm expecting Novavax shares to spike higher as its vaccine starts receiving authorization around the world in the fourth quarter. Novavax's vaccine candidate will be popular both as a booster shot and as an initial vaccine for the majority of the world who are unvaccinated. And Novavax is leading in the race to combine the COVID-19 vaccine with a flu vaccine. The company just kicked off a combo trial in Australia involving 640 people who have been vaccinated against both diseases with a single shot.\n2. Sorrento Therapeutics: Don't sleep on this name\nGeorge Budwell(Sorrento Therapeutics):The clinical-stage biotech Sorrento Therapeutics rose to prominence last year thanks to its impressive lineup of experimental COVID-19 diagnostics and biologic therapies. The biotech's stock, in fact, gained a whopping 144% from January 2020 to March 2021 mostly because of its broad spectrum of COVID-19 vaccine candidates. Sorrento's shares, however, have now lost almost a quarter of their value over the past 180 days. Investors have apparently moved on to greener pastures, given the company's inability to bring even one of its various COVID-19 vaccine candidates to market in the United States.\nThe core issue is that multiple biopharmas have been successful at developing and subsequently marketing COVID-19 vaccines, tests, and therapeutic antibodies in key markets like the U.S. and European Union over the last few months. Meanwhile, Sorrento is still on the hunt for its first major regulatory win. What's important for potential investors to understand, though, is that the pandemic is far from over. COVID-19 is highly likely to morph into a seasonal respiratory ailment. As such, investors shouldn't necessarily write off latecomers such as Sorrento. Eventually, the company could realize a healthy revenue stream from a COVID-19 diagnostic and/or therapeutic.\nIt is entirely possible that Sorrento could garner multiple regulatory approvals for its COVID-19 vaccine candidates in the U.S. within the next calendar year, which would be a major boon for its stock. That said, this mid-cap biotech stock will surely remain on the volatile side until the company lands a Food and Drug Administration approval within the COVID-19 space. Invest accordingly.\n3. InMode stock will spike as the world reopens\nPatrick Bafuma (InMode):As the world opens back up and people feel more comfortable gathering, the aesthetics market is sure to heat up. That's why my pick for a COVID-19 vaccine stock to double is InMode, the self-proclaimed leading global provider of innovative, minimally invasive aesthetic and wellness solutions, with strong brand recognition.\nUsing a razor-and-blades model, the company markets a medical device system and associated consumables that provide an energy source for body contouring. Utilized by multiple medical specialists, including plastic surgeons, dermatologists, gynecologists, ENTs, and ophthalmologists, InMode claims its procedures are longer lasting than laser treatment and less invasive than typical body sculpting procedures like liposuction.\nAnd this $5.2 billion aesthetics company is firing on all cylinders.In the most recent quarter, InMode reported record revenue of $87.3 million, representing an increase of 184% compared to the second quarter of 2020. Total second-quarter sales outside of the U.S. were $30.9 million, more than triple what it reported during the same period last year. This torrid international growth represented 35% of its total revenue compared to 22% of its total revenue in Q2 2020. Currently operating in 68 countries, the company enjoys a massive runway for continued growth.\nAs the world slowly returns to normal, consumers are seeking out treatments that they had delayed due to COVID-19. \"Our demand is strong,\" chief medical officer Spero Theodorou noted on the last conference call. \"It's solid all the way into September. Waiting lists ... (are) about a month out.\"\nTheodorou went on to say, \"Over one-third of the new patients coming in have never had (any aesthetics procedure) done before.\" This indicates that InMode has expanded the body contouring market, which had already reached $6.2 billion worldwide in 2020 despite the COVID-19 pandemic. This market is expected to grow at a compound annual growth rate of 7.2% into 2026, so there is plenty of room to run for InMode.\nWith many of us either in the house or masked up since March 2020, I expect continued growth for this aesthetics device maker as COVID-19 wanes. Despite InMode already being up over 180% since the start of 2021, the company has a huge runway, and its razor-and-blades business model continues to be an effective positioning strategy. InMode is already profitable with adjusted diluted earnings per share in Q2 coming in at $1.02 compared to $0.24 per diluted share for the same quarter of 2020. InMode looks like it's shaping up to double its share price again.","news_type":1,"symbols_score_info":{"INMD":0.9,"NVAX":0.9,"SRNE":0.9}},"isVote":1,"tweetType":1,"viewCount":2413,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

3 COVID Stocks That Might Double Soon<blockquote>3只新冠股票可能很快翻倍</blockquote>

评论（2）

热议股票